Search

Your search keyword '"Goodwin, Anne"' showing total 56 results

Search Constraints

Start Over You searched for: Author "Goodwin, Anne" Remove constraint Author: "Goodwin, Anne" Database Unpaywall Remove constraint Database: Unpaywall
56 results on '"Goodwin, Anne"'

Search Results

3. Demographic and Disease-Related Predictors of Socioemotional Development in Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas: An Exploratory Study

8. Cediranib phase‐II study in children with metastatic alveolar soft‐part sarcoma (ASPS)

13. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas

16. Early detection of transformation of plexiform neurofibromas to malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

17. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors

19. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas

20. Phase I trial and pharmacokinetic (PK) study of satraplatin in children and young adults with refractory solid tumors including brain tumors.

23. A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

24. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group

25. Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group

26. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors

28. Abstract A5: Phase I trial and pharmacokinetic study of cediranib in children with recurrent or refractory solid tumors

31. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors

35. A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

44. Book Cover

48. CorresondenceChartered Counselling PsychologistsPsychologists in PICUsThe unresolved dilemmas at AshworthMental Health Review TribunalPsychology managingSoiling in children“The antipsychiatry placement”

Catalog

Books, media, physical & digital resources